ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: BCR-ABL kinase domain mutations are an important cause of resistance to tyrosine kinase inhibitors (TKIs) in chronic myeloid leukaemia (CML) of which T315I is the most treatment-resilient.